Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Transcriptional Control and Signal Transduction

IL-6, but not IFN-γ, triggers apoptosis and inhibits in vivo growth of human malignant T cells on STAT3 silencing

Leukemia volume 23, pages 2102–2108 (2009)Cite this article

Abstract

STAT1 and STAT3 are the main mediators of the signaling of interferons (IFNs) and of gp130 cytokines, respectively. Neoplastic T lymphocytes frequently become resistant to the IFN-γ/STAT1 apoptotic pathway, often because of the downregulation of the IFN-γR2 receptor chain. Many studies suggest that cross-regulation between different STATs, in particular between STAT1 and STAT3, may profoundly affect cytokine/growth factor signaling. Here, the function of STAT3 in the negative regulation of STAT1 apoptotic pathway was investigated by RNA interference-mediated STAT3 silencing in human malignant T lymphocytes. In STAT3-depleted cells, interleukin (IL)-6 acquired the capacity to induce apoptosis, correlating with prolonged STAT1 activation and the induction of major histocompatibility complex (MHC) class I expression. In contrast, in the absence of STAT3, IFN-γ could slightly enhance apoptosis but its ability to induce MHC class I expression was unchanged. Accordingly, IL-6, but not IFN-γ, could significantly impair the in vivo growth of STAT3-depleted human neoplastic T lymphocytes transplanted into severe combined immunodeficient mice. Therefore, treatment with IL-6 and simultaneous STAT3 silencing may represent a potential therapeutic approach to control the expansion of IFN-γ-unresponsive neoplastic T cells.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4

Similar content being viewed by others

References

  1. Levy DE, Darnell Jr JE . Stats: transcriptional control and biological impact. Nat Rev Mol Cell Biol 2002; 3: 651–662.

    Article  CAS  Google Scholar 

  2. Wormald S, Hilton DJ . Inhibitors of cytokine signal transduction. J Biol Chem 2004; 279: 821–824.

    Article  CAS  Google Scholar 

  3. Costa-Pereira AP, Tininini S, Strobl B, Alonzi T, Schlaak JF, Is'harc H et al. Mutational switch of an IL-6 response to an interferon-gamma-like response. Proc Natl Acad Sci USA 2002; 99: 8043–8047.

    Article  CAS  Google Scholar 

  4. Qing Y, Stark GR . Alternative activation of STAT1 and STAT3 in response to interferon-gamma. J Biol Chem 2004; 279: 41679–41685.

    Article  CAS  Google Scholar 

  5. Tanabe Y, Nishibori T, Su L, Arduini RM, Baker DP, David M . Cutting edge: role of STAT1, STAT3, and STAT5 in IFN-alpha beta responses in T lymphocytes. J Immunol 2005; 174: 609–613.

    Article  CAS  Google Scholar 

  6. Gimeno R, Lee CK, Schindler C, Levy DE . Stat1 and Stat2 but not Stat3 arbitrate contradictory growth signals elicited by alpha/beta interferon in T lymphocytes. Mol Cell Biol 2005; 25: 5456–5465.

    Article  CAS  Google Scholar 

  7. Stephanou A, Latchman DS . Opposing actions of STAT-1 and STAT-3. Growth Factors 2005; 23: 177–182.

    Article  CAS  Google Scholar 

  8. Bromberg JF, Wrzeszczynska MH, Devgan G, Zhao Y, Pestell RG, Albanese C et al. Stat3 as an oncogene. Cell 1999; 98: 295–303.

    Article  CAS  Google Scholar 

  9. Ikeda H, Old LJ, Schreiber RD . The roles of IFN gamma in protection against tumor development and cancer immunoediting. Cytokine Growth Factor Rev 2002; 13: 95–109.

    Article  CAS  Google Scholar 

  10. Pestka S, Kotenko SV, Muthukumaran G, Izotova LS, Cook JR, Garotta G . The interferon gamma (IFN-gamma) receptor: a paradigm for the multichain cytokine receptor. Cytokine Growth Factor Rev 1997; 8: 189–206.

    Article  CAS  Google Scholar 

  11. Kaplan DH, Shankaran V, Dighe AS, Stockert E, Aguet M, Old LJ et al. Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice. Proc Natl Acad Sci USA 1998; 95: 7556–7561.

    Article  CAS  Google Scholar 

  12. Dunn GP, Sheehan KC, Old LJ, Schreiber RD . IFN unresponsiveness in LNCaP cells due to the lack of JAK1 gene expression. Cancer Res 2005; 65: 3447–3453.

    Article  CAS  Google Scholar 

  13. Regis G, Conti L, Boselli D, Novelli F . IFNgammaR2 trafficking tunes IFNgamma-STAT1 signaling in T lymphocytes. Trends Immunol 2006; 27: 96–101.

    Article  CAS  Google Scholar 

  14. Novelli F, Di Pierro F, Francia di Celle P, Bertini S, Affaticati P, Garotta G et al. Environmental signals influencing expression of the IFN-gamma receptor on human T cells control whether IFN-gamma promotes proliferation or apoptosis. J Immunol 1994; 152: 496–504.

    CAS  PubMed  Google Scholar 

  15. Conti L, Regis G, Longo A, Bernabei P, Chiarle R, Giovarelli M et al. In the absence of IGF-1 signaling, IFN-gamma suppresses human malignant T-cell growth. Blood 2007; 109: 2496–2504.

    Article  CAS  Google Scholar 

  16. Durelli L, Conti L, Clerico M, Boselli D, Contessa G, Ripellino P et al. T Helper 17 cells expand in multiple sclerosis and are inhibited by interferon-BETA. Ann Neurol 2009; 65: 499–509.

    Article  CAS  Google Scholar 

  17. Novelli F, D'Elios MM, Bernabei P, Ozmen L, Rigamonti L, Almerigogna F et al. Expression and role in apoptosis of the alpha- and beta-chains of the IFN-gamma receptor on human Th1 and Th2 clones. J Immunol 1997; 159: 206–213.

    CAS  PubMed  Google Scholar 

  18. Regis G, Bosticardo M, Conti L, De Angelis S, Boselli D, Tomaino B et al. Iron regulates T-lymphocyte sensitivity to the IFN-gamma/STAT1 signaling pathway in vitro and in vivo. Blood 2005; 105: 3214–3221.

    Article  CAS  Google Scholar 

  19. Fleisher TA, Dorman SE, Anderson JA, Vail M, Brown MR, Holland SM . Detection of intracellular phosphorylated STAT-1 by flow cytometry. Clin Immunol 1999; 90: 425–430.

    Article  CAS  Google Scholar 

  20. Friedman RL, Stark GR . alpha-Interferon-induced transcription of HLA and metallothionein genes containing homologous upstream sequences. Nature 1985; 314: 637–639.

    Article  CAS  Google Scholar 

  21. Bernabei P, Coccia EM, Rigamonti L, Bosticardo M, Forni G, Pestka S et al. Interferon-gamma receptor 2 expression as the deciding factor in human T, B, and myeloid cell proliferation or death. J Leukoc Biol 2001; 70: 950–960.

    CAS  PubMed  Google Scholar 

  22. Schroder K, Hertzog PJ, Ravasi T, Hume DA . Interferon-gamma: an overview of signals, mechanisms and functions. J Leukoc Biol 2004; 75: 163–189.

    Article  CAS  Google Scholar 

  23. Novelli F, Bernabei P, Ozmen L, Rigamonti L, Allione A, Pestka S et al. Switching on of the proliferation or apoptosis of activated human T lymphocytes by IFN-gamma is correlated with the differential expression of the alpha- and beta-chains of its receptor. J Immunol 1996; 157: 1935–1943.

    CAS  PubMed  Google Scholar 

  24. Bernabei P, Bosticardo M, Losana G, Regis G, Di Paola F, De Angelis S et al. IGF-1 down-regulates IFN-gamma R2 chain surface expression and desensitizes IFN-gamma/STAT-1 signaling in human T lymphocytes. Blood 2003; 102: 2933–2939.

    Article  CAS  Google Scholar 

  25. Xi S, Gooding WE, Grandis JR . In vivo antitumor efficacy of STAT3 blockade using a transcription factor decoy approach: Implications for cancer therapy. Oncogene 2005; 24: 970–979.

    Article  CAS  Google Scholar 

  26. Gao L, Zhang L, Hu J, Li F, Shao Y, Zhao D et al. Down-regulation of signal transducer and activator of transcription 3 expression using vector-based small interfering RNAs suppresses growth of human prostate tumor in vivo. Clin Cancer Res 2005; 11: 6333–6341.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

This work was supported by grants from Associazione Italiana per la Ricerca sul Cancro (AIRC), Compagnia di San Paolo (special project Oncology), Ministero dell'Istruzione, dell'Università e della Ricerca (MIUR), ex 40% and Fondo per gli Investimenti della Ricerca di Base (FIRB), Ministero della Salute, Progetto integrato Oncologia; Regione Piemonte: Ricerca Industriale e Sviluppo Precompetitivo (ONCOPROT), Ricerca Industriale ‘Converging Technologies’ (BIOTHER), Ricerca Sanitaria Finalizzata, by a fellowship from FIRB (GR).

Author information

Author notes

  1. G Regis

    Present address: 4Current address: Molecular Biotechnology Center, Department of Genetics, Biology and Biochemistry, University of Turin, Turin, Italy.,

Authors and Affiliations

  1. The Center for Experimental Research and Medical Studies (CERMS), San Giovanni Battista Hospital—Molinette, Turin, Italy

    G Regis, L Icardi, L Conti, R Chiarle, R Piva, M Giovarelli & F Novelli

  2. Department of Medicine and Experimental Oncology, University of Turin, Turin, Italy

    G Regis, L Conti, M Giovarelli & F Novelli

  3. Department of Genetics, The Molecular Biotechnology Center (MBC), Biology and Biochemistry, University of Turin, Turin, Italy

    G Regis & V Poli

Authors
  1. G Regis
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. L Icardi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. L Conti
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. R Chiarle
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. R Piva
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. M Giovarelli
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. V Poli
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. F Novelli
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to F Novelli.

Additional information

Supplementary Information accompanies the paper on the Leukemia website (http://www.nature.com/leu)

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Cite this article

Regis, G., Icardi, L., Conti, L. et al. IL-6, but not IFN-γ, triggers apoptosis and inhibits in vivo growth of human malignant T cells on STAT3 silencing. Leukemia 23, 2102–2108 (2009). https://doi.org/10.1038/leu.2009.139

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/leu.2009.139

Keywords

This article is cited by

Search

Advanced search

Quick links